Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 11:04 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 817–840 of 4,243 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Immune Deficiency Disorder Clear all
Completed Phase 3 Interventional

The Safety and Effectiveness of Lamivudine Plus Zidovudine, Used With and Without 1592U89, in HIV-1 Infected Patients Who Have Never Taken Anti-HIV Drugs

NCT00002389
View directory record Official record
Conditions
HIV Infections
Interventions
Abacavir sulfate, Lamivudine, Zidovudine
Drug
Lead sponsor
Glaxo Wellcome
Industry
Eligibility
13 Years and older
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
13
States / cities
Berkeley, California • Los Angeles, California • Washington D.C., District of Columbia + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 20, 2026, 11:04 AM EDT
Completed Early Phase 1 Interventional

Intra-lesional Nivolumab Therapy for Limited Cutaneous Kaposi Sarcoma

NCT03316274
View directory record Official record
Conditions
Kaposi Sarcoma, HIV/AIDS, Immunosuppression
Interventions
Nivolumab
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 25, 2024 · Synced Oct 20, 2026, 11:04 AM EDT
Terminated Phase 2 Interventional Results available

HIV Reservoir Reduction With Interleukin-2

NCT03308786
View directory record Official record
Conditions
HIV Infection
Interventions
Recombinant Interleukin-2
Drug
Lead sponsor
Case Western Reserve University
Other
Eligibility
18 Years to 65 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 28, 2022 · Synced Oct 20, 2026, 11:04 AM EDT
Completed Phase 1 Interventional

3BNC117-LS and 10-1074-LS Plus N-803 (bNAb+N-803)

NCT05245292
View directory record Official record
Conditions
Human Immunodeficiency Virus
Interventions
3BNC117-LS, 10-1074-LS, N803
Drug
Lead sponsor
Rockefeller University
Other
Eligibility
18 Years to 70 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
3
States / cities
New York, New York • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 31, 2026 · Synced Oct 20, 2026, 11:04 AM EDT
Completed Phase 2 Interventional

Phase II Evaluation of Low-Dose Oral Etoposide for the Treatment of Relapsed or Progressed AIDS-Related Kaposi's Sarcoma After Systemic Chemotherapy

NCT00000807
View directory record Official record
Conditions
Sarcoma, Kaposi, HIV Infections
Interventions
Etoposide
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
12 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2000
U.S. locations
20
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2021 · Synced Oct 20, 2026, 11:04 AM EDT
Completed Phase 1 Interventional

Endothelial Dysfunction as a Risk Factor in HIV Study

NCT00039663
View directory record Official record
Conditions
HIV Infections
Interventions
Pravastatin, Gemfibrozil, Rosiglitazone
Drug
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
Not listed
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 20, 2026, 11:04 AM EDT
Completed No phase listed Observational

Accuracy Evaluation of the BD FACS Presto System

NCT02396355
View directory record Official record
Conditions
Acquired Immunodeficiency Syndrome
Interventions
Investigational BD FACSPresto System, BD FACSCalibur flow cytometer, Sysmex hematology analyzer KX-21
Device
Lead sponsor
Becton, Dickinson and Company
Industry
Eligibility
Not listed
Enrollment
583 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
3
States / cities
Los Angeles, California • San Francisco, California • San Jose, California
Source: ClinicalTrials.gov public record
Updated Feb 9, 2017 · Synced Oct 20, 2026, 11:04 AM EDT
Completed Not applicable Interventional Results available

Healing Hearts and Mending Minds in Older Adults Living With HIV

NCT02711878
View directory record Official record
Conditions
HIV, Cardiovascular Disease, AIDS
Interventions
Let's Move Program, Let's Flex Program, Group Motivational Interviewing
Behavioral
Lead sponsor
Emory University
Other
Eligibility
40 Years to 89 Years
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
3
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jul 6, 2023 · Synced Oct 20, 2026, 11:04 AM EDT
Completed Phase 2 Interventional

Treatment Success and Failure in HIV-Infected Subjects Receiving Indinavir in Combination With Nucleoside Analogs: A Rollover Study for ACTG 320

NCT00000885
View directory record Official record
Conditions
HIV Infections
Interventions
Indinavir sulfate, Abacavir sulfate, Nelfinavir mesylate, Efavirenz, Levocarnitine, Adefovir dipivoxil, Lamivudine, Stavudine, Zidovudine, Didanosine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
16 Years and older
Enrollment
440 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2003
U.S. locations
52
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 32 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2021 · Synced Oct 20, 2026, 11:04 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

The Use of Bacteriophage Phi X174 to Assess the Immune Competence of HIV-Infected Patients In Vivo

NCT00001540
View directory record Official record
Conditions
HIV Infections
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1996 – 2000
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 20, 2026, 11:04 AM EDT
Completed Phase 1 Interventional Results available

Single Dose Pharmacokinetics of Doravirine in HIV-infected Pregnant Women

NCT04900974
View directory record Official record
Conditions
HIV Infections, Pregnancy Related
Interventions
Doravirine
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older · Female only
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Oct 20, 2026, 11:04 AM EDT
Completed Phase 3 Interventional

Study of NGX-4010 for the Treatment of Painful HIV-Associated Neuropathy

NCT00064623
View directory record Official record
Conditions
HIV Infections, Peripheral Nervous System Diseases, Pain
Interventions
Capsaicin Dermal Patch
Drug
Lead sponsor
NeurogesX
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
35
States / cities
Phoenix, Arizona • Berkeley, California • San Diego, California + 29 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2008 · Synced Oct 20, 2026, 11:04 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

IMARA, Adapting SiHLE for Detained African American Adolescent Females

NCT00746369
View directory record Official record
Conditions
HIV Infections
Interventions
IMARA HIV Prevention Intervention
Behavioral
Lead sponsor
Emory University
Other
Eligibility
13 Years to 17 Years · Female only
Enrollment
188 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2012
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Nov 19, 2013 · Synced Oct 20, 2026, 11:04 AM EDT
Completed Phase 4 Interventional

Efficacy, Safety & Tolerability of Switching EFV/TDF/FTC to BIC/FTC/TAF in Virologically Suppressed Adults With HIV-1

NCT03502005
View directory record Official record
Conditions
Human Immunodeficiency Virus
Interventions
bictegravir/emtricitabine/tenofovir alafenamide
Drug
Lead sponsor
Midland Research Group, Inc.
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Oakland Park, Florida
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 20, 2026, 11:04 AM EDT
Active, not recruiting Phase 2 Interventional

A Study of Islatravir (ISL) and Ulonivirine (ULO) Once Weekly (QW) in Virologically Suppressed Adults With Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8591B-060)

NCT06891066
View directory record Official record
Conditions
Human Immunodeficiency Virus Type 1 (HIV-1) Infection
Interventions
ISL, ULO, BIC/FTC/TAF
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
11
States / cities
San Francisco, California • West Hollywood, California • Washington D.C., District of Columbia + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2025 · Synced Oct 20, 2026, 11:04 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Effects of a Uridine Supplement on HIV Infected Adults With Lipoatrophy

NCT00307164
View directory record Official record
Conditions
HIV Infections, Lipoatrophy
Interventions
NucleomaxX, NucleomaxX placebo
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
167 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
29
States / cities
Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 20 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Oct 20, 2026, 11:04 AM EDT
Completed Phase 1 Interventional

Underlying Abnormalities in Fat and Muscle Leading to Lipodystrophy Syndrome

NCT00006185
View directory record Official record
Conditions
HIV Infections, Lipodystrophy, Insulin Resistance
Interventions
Avandia administration for 6-12 weeks
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years to 55 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2003
U.S. locations
1
States / cities
Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated Mar 2, 2010 · Synced Oct 20, 2026, 11:04 AM EDT
Completed Phase 1 Interventional Results available

Effect of N-803 on B Cell Follicles in Antiretroviral Treated HIV Disease

NCT04808908
View directory record Official record
Conditions
Hiv, HIV Infections, AIDS
Interventions
N-803
Biological
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
2
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 2, 2024 · Synced Oct 20, 2026, 11:04 AM EDT
Completed No phase listed Observational

T-cell Responses to Concurrent HIV and Herpesvirus Infections

NCT03996018
View directory record Official record
Conditions
HIV, HIV Infections
Interventions
T-cell lymphocyte responses
Other
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
18 Years and older
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 15, 2024 · Synced Oct 20, 2026, 11:04 AM EDT
Completed Not applicable Interventional

A Study of 1592U89 in HIV-Infected Children

NCT00002197
View directory record Official record
Conditions
HIV Infections
Interventions
Abacavir sulfate
Drug
Lead sponsor
Glaxo Wellcome
Industry
Eligibility
6 Months to 13 Years
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Research Triangle Park, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 20, 2026, 11:04 AM EDT
Completed Phase 1Phase 2 Interventional

A Dose Response and Safety Study of Procaine HCl in HIV-Infected Patients

NCT00299338
View directory record Official record
Conditions
HIV Infections
Interventions
SP01A
Drug
Lead sponsor
Samaritan Pharmaceuticals, Inc
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2001
U.S. locations
1
States / cities
West Hollywood, California
Source: ClinicalTrials.gov public record
Updated Apr 3, 2006 · Synced Oct 20, 2026, 11:04 AM EDT
Completed Phase 2 Interventional

An Open-Label, Pilot Study to Evaluate the Development of Resistance to Nevirapine (BI-RG-587) in HIV-Infected Patients With CD4 Cell Count >= 500/mm3

NCT00000747
View directory record Official record
Conditions
HIV Infections
Interventions
Nevirapine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Mar 1, 2011 · Synced Oct 20, 2026, 11:04 AM EDT
Completed Not applicable Interventional

Assisted Partner Services and HIVST in Western Kenya

NCT04774835
View directory record Official record
Conditions
Hiv
Interventions
HIVST, Standard aPS
Diagnostic Test
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
4,941 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 19, 2022 · Synced Oct 20, 2026, 11:04 AM EDT
Terminated Phase 1 Interventional

Cognitive Behavioral Therapy to Help HIV Infected Adults With Depression to Adhere to Antiretroviral Therapy

NCT00509340
View directory record Official record
Conditions
Depression, HIV Infection
Interventions
Cognitive behavioral therapy (CBT)
Behavioral
Lead sponsor
RAND
Other
Eligibility
18 Years to 60 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
Torrance, California
Source: ClinicalTrials.gov public record
Updated Jun 21, 2013 · Synced Oct 20, 2026, 11:04 AM EDT